Breast Clinical Trials


With an emphasis on transdisciplinary translational research, the OSUCCC-James facilitates investigator-initiated early phase clinical trials and participates in many cooperative groups.

Protocol No.PITitle
OSU-0107Doreen AgneseProspective Cohort Study of BRCA1 & BRCA2 Carriers
OSU-10129Dawn AllainThe Value of Genetic Counselors in Genetic Testing for Hereditary Breast-Ovarian Cancer
OSU-9942Barbara AndersenStress Immunity & Breast Cancer Recurrence
OSU-13127Barbara AndersenPsychological Changes in Breast Cancer Patients Participating in a Biobehavioral Intervention
CALGB-60202Clara BloomfieldEmbedded companion to CALGB 40101: Drug Metabolism and Transport PG in Breast CA patients on CALGB 40101
OSU-09142William CarsonMyeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NSABP-B-43William FarrarA Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
NSABP-B-47William FarrarRandomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
OSU-13093William FarrarNSABP B-50-I: A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
SWOG-S1207William FarrarPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.
OSU-12033Gayle GordilloMASTECTOMY RECONSTRUCTION OUTCOMES CONSORTIUM (MROC) STUDY
OSU-10078Janice Kiecolt-GlaserFast Food, Fatigue, and Inflammation: The FOOD Study
OSU-13194Janice Kiecolt-GlaserThe IMPACT Study: Inflammatory Responses, Mood and Physical Fitness after Cancer Treatment
OSU-14002Janice Kiecolt-GlaserThe HEART Study: Heart Health in Breast Cancer Survivors
ALLIANCE-A011106Rachel LaymanALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
OSU-13049Joanne LesterThe Effect of Comprehensive Survivorship Care on Distress in Leukemia and Breast Cancer Survivors
OSU-0252Joanne LesterEvaluation and Treatment of Urogenital Atrophy in High Risk Breast Patients and Breast Cancer Survivors
OSU-11092Joanne LesterEffect of Survivorship Care Planning on Distress: A Randomized Control Trial with Leukemia and Breast Cancer Survivors.
SWOG-S1007Maryam LustbergA Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
OSU-13010Maryam LustbergLongitudinal Evaluation of Taxane induced neuropathy in early stage breast cancer
OSU-14068Maryam LustbergNutritional Assessment in Patients with Breast Cancer During Chemotherapy
OSU-14157Maryam LustbergCompassionate use of ABT 888 for a patient with metastatic breast cancer
OSU-14077Erin MacraeA Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06650808 in Patients with Advanced Solid Tumors
OSU-13117Erin MacraeA Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination with GSK2141795 in Patients with Advanced Triple Negative Breast Cancer
OSU-13150Erin MacraeA randomized Phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs. Paclitaxel in combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT Trial)
OSU-12067Erin MacraeDecision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies
CALGB-60701Ewa MrozekEmbedded Companion to CALGB-40601
CALGB-150702Ewa MrozekEmbedded Companion to CALGB-40601
OSU-09012Douglas PostDeveloping a communication Tool for Appalachian Breast Cancer Survivors
OSU-12156Douglas PostIncreasing Adherence to Adjuvant Hormonal Therapy among Breast Cancer Patients: Phase I - Intervention Development
OSU-13252Douglas PostIncreasing Adherence to Adjuvant Hormonal Therapy among Breast Cancer Patients: Phase 2 Pilot Test of Intervention for Feasibility
OSU-07015Stephen Povoski8 Gauge Mammotome Vacuum-Assisted Biopsy Technique: Retrospective Chart Review
OSU-07016Stephen PovoskiAssessment of Nine Standardized Quadrantectomy Resection Margins During Breast Conservation Surgery for Breast Cancer: Retrospective Chart Review
ECOG-E2108Stephen PovoskiA Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
RTOG-1119Allison QuickPHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY IN COMBINATION WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER A COLLABORATIVE STUDY OF RTOG AND KROG
CALGB-150605Bhuvaneswari RamaswamyEmbedded Companion Study to CALGB-40503
CALGB-60605Bhuvaneswari RamaswamyEmbedded Companion Study to CALGB-40503
CALGB-150804Bhuvaneswari RamaswamyEmbedded companion study to CALGB 70604
CALGB-60803Bhuvaneswari RamaswamyEmbedded companion study to CALGB 70604
OSU-13237Bhuvaneswari RamaswamyA Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease
PRECOG-PRE0102Bhuvaneswari RamaswamyRandomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) plus Everolimus in Post-Menopausal Patients with Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
OSU-13153Bhuvaneswari RamaswamyCompassionate Use of ABT-888 for a Patient with Metastatic Breast Cancer
OSU-13132Roger RatcliffCognitive Deficits in Decision-Making
OSU-11127Leigha Senter-JamiesonThe impact of pregnancy during and after breast cancer on survival in carriers of BRCA1 and BRCA2 mutations
OSU-07088Charles ShapiroThe Columbus Breast Cancer Tissue Bank
OSU-0109Charles ShapiroHuman Breast Cancer and National Breast Tissue Bank
OSU-05082Amanda TolandVariants in High Risk Breast Cancer Genes and Contribution to Cancer Risk.
OSU-05102Amanda TolandIdentification of Human Cancer Susceptibility & Resistance Genes.
OSU-10152Robert WesolowskiPhase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
CALGB-150709Robert WesolowskiEmbedded Companion to CALGB-40603
CALGB-60703Robert WesolowskiEmbedded Companion to CALGB-40603
OSU-12020Robert WesolowskiMINT I Multi-Institutional Neo-adjuvant Therapy MammaPrint project I
OSU-13211Robert WesolowskiAn Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors
OSU-13260Julia WhiteIMPACT OF THE ONCOTYPE D:x®DCIS SCORE ON TREATMENT DECISION MAKING IN PATIENTS WITH DUCTAL CARCINOMA IN SITU
RTOG-1304Julia WhiteA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
CALGB-40903Lisa YeePHASE II STUDY OF NEOADJUVANT LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE DUCTAL CARCINOMA IN SITU [DCIS)
OSU-13034Lisa YeeNanoemulsion curcumin for obesity, inflammation and breast cancer prevention a pilot trial
OSU-0253Lisa YeeBreast Fine Needle Aspiration and Breast Duct Fluid Collection in High Risk Breast Patients.
OSU-9990Lisa YeeFatty Acids & Peroxisome Proliferator-Activated Receptors in Breast Cancer Prevention

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu